Abstract
The case of a 34-yr-old Caucasian male with Graves’ disease presenting with a flaccid quadriplegia and severe hypokalemia is reported. The weakness was prevalent at the lower extremities and began during nocturnal sleep, after a strenuous physical exertion performed during the day. Correction of hypokalemia promptly reversed the quadriplegia. The occurrence of hypokalemic thyrotoxic periodic paralysis several months after the beginning of thyrotoxic symptoms, and the normal insulin serum levels on admission differentiate this patient from most of the previously reported cases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
DeLong G.R., Adams R. The neuromuscular system and brain in thyrotoxicosis. In: Braverman LE., Utiger R.D. (Eds.), Werner and Ingbar’s The Thyroid. JB Lippincott Company, Philadelphia, 1991, p. 793.
Ptacek L.J., Griggs R.C. Periodic paralysis. In: Isselbacher K.J., Braunwald E., Wilson J.D., Martin J.B., Fauci A.S., Kasper D.L. (Eds.), Harrison’s Principles of Internal Medicine. McGraw-Hill Inc, New York, 1994, p. 2396.
Okinaka S., Shizume K., Lino S., Watanabe A., Irie M., Noguchi A., Kuma S., Kuma K., Ito T. The association of periodic paralysis and hyperthyroidism in Japan. J. Clin. Endocrinol. Metab. 17: 1454, 1957.
McFadzean A.J.S., Yeung R. Periodic paralysis complicating thyrotoxicosis in Chinese. Br. Med. J. 1: 451, 1967.
Kelley D.E., Gharib H., Kennedy F.P., Duda R.J., McManis P.G. Thyrotoxic periodic paralysis. Report of 10 cases and review of electromyographic findings. Arch. Intern. Med. 149: 2597, 1989.
Yeo P.P.B., Chan S.H., Liu S.H.F., Wee G.B., Lim P., Cheah J.S. HLA and thyrotoxic periodic paralysis. Br. Med. J. 2: 930, 1978.
Ali K. Hypokalaemic periodic paralysis complicating thyrotoxicosis. Br. Med. J. 2: 503, 1975.
Shah N., Kussman M.J., Tulgan H. Familial periodic paralysis and hyperthyroidism. New York State J. Med. 79: 1770, 1979.
Pandolfi C., Pellegrini L., Vitelli E., Sbalzarini G. Paralisi periodica tireotossica e morbo di Graves. Descrizione di un caso HLA-CW7 positivo. Min. Endocrinol. 16: 153, 1991.
Celani M.F. Levothyroxine suppressive therapy in the medical management of nontoxic benign multinodular goiter. Exp. Clin. Endocrinol. 101: 326, 1993.
Hu R., Beck C., Chang Y.B., Degroot L.J. HLA class II genes in Graves’ disease. Autoimmunity 12: 103, 1992.
Kelly T.M., Fishman L.M. Thyrotoxic periodic paralysis in a Black male. J. Endocrinol. Invest. 7: 517, 1984.
Marx A., Ruppersberg J.P., Pietrzyz C., Rudel R. Thyrotoxic periodic paralysis and the sodium/potassium pump. Muscle and Nerve 12: 810, 1989.
Miller D., delCastillo J., Tsang T.K. Severe hypokalemia in thyrotoxic periodic paralysis. Am. J. Emerg. Med. 7: 584, 1989.
Engel A. Thyroid function and periodic paralysis. Am. J. Med. 30: 327, 1961.
Chan A., Shinde R., Chow C.C., Cockram C.S., Swaminathan R. In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. Br. Med. J. 303: 1096, 1991.
Fontaine B., Vale-Santos J., Jucat-Rott K., Reboul J., Plassart E., Rime C.S., Elbaz A., Heine R., Guimãraes J., Weissenbach J., Baumann N., Fardeau M., Lehmann-Horn F. Mapping of the hypokalaemic periodic paralysis (HypoPP) locus to chromosome 1q31–32 in three European families. Nature Genet. 6: 267, 1994.
Maresca M.C., Calconi G., Amici G.P., Teodori T., Da Porto A. Ipopotassiemia e rabdomiolisi. Descrizione di tre casi a diversa eziologia. Min. Med. 79: 55, 1988.
Shishiba Y., Shimizu T., Saito T., Shizume K. Elevated immunoreactive insulin concentrations during spontaneous attacks in thyrotoxic periodic paralysis. Metabolism 21: 285, 1974.
Lee K.O., Taylor E.A., Oh V.M.S., Cheah J.S., Aw S.E. Hyperinsulinaemia in thyrotoxic hypokalaemic periodic paralysis. Lancet 337: 1063, 1991.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Celani, M.F., Bonati, M.E. & Cavalli, M. Hypokalemic thyrotoxic periodic paralysis in a Caucasian male with Graves’ disease. J Endocrinol Invest 18, 228–231 (1995). https://doi.org/10.1007/BF03347807
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03347807